Table 1 Patient characteristics
Characteristic | Ibrutinib patients (n=64) |
|---|---|
Median age, years (range) | 71 (40–92) |
⩾70 Years | 56.3% |
⩾75 Years | 29.7% |
Male, % | 64.1% |
Median weight, kg (range) | 76 (44–114) |
Male | 80 (62–114) |
Female | 58 (44–84) |
Median number of prior therapies (range) | 2 (0–6) |
0 | 18% |
1 | 27.9% |
2 | 32.8% |
⩾3 | 21.3% |
Del17p or TP53 mutation, % | 47.6% |
Median platelet count, G/l (range) | 114.5 (28–307) |
Median observation period, months (range) | 10.9 (0.5–35.3) |
Patients with at least one bleeding event | 39/64 (60.9%) |
CTC grade 1 or 2 | 37 |
CTC grade 3 | 2 |
CTC grade 4 or more severe | None |
Total number of bleeding events during follow-up | 87 |
CTC grade 1 or 2 | 85/87 (97.7%) |
CTC grade 3 | 2/87 (2.3%) |
CTC grade 4 or more severe | None |
Total number of patients in whom ibrutinib was paused or discontinued because of; | 11/64 (17.2%) |
Progression of disease/death | 2/64 (3.1%) |
Adverse event | 6/64 (9.4%) |
Planned surgery | 3/64 (4.7%) |
Total number of patients still responding and on ibrutinib after a median of 10.9 months (0.5–35.3) | 60/64 (93.8%) |
